- Alimentary System
- Cardiovascular & Hematopoietic System
- Respiratory System
- Neuro-Muscular System
- Hormones
- Contraceptive Agents
- Antibiotics
- Other Chemotherapeutics
- Genito-Urinary System
- Metabolism (Anti-Cholesterol/Osteoporosis)
- Eye, Ear, Mouth & Throat
- Dermatologicals
- Anaesthetics – Local & General
- Allergy & Immune System
- Antidotes & Detoxifying Agents
- Intravenous & Other Sterile Solutions
- Miscellaneous
= Chemical Compound
= Indications
= Dosage
= Contraindication
= Special Precautions
= Adverse Reactions
= Drug-Drug Interaction
Antidotes & Detoxifying Agents
Dimercaprol.
Heavy metal intoxication.
Hepatic insufficiency unless due to arsenic poisoning;
treatment of Fe, cadmium or selenium poising, alone in lead
poisoning, G6PD deficiency.
Hypertension, impaired renal function, elderly, pregnancy
or lactation.
(May be reduced by 4 hr interyal between doses, 30-60
mg, ephedrine orally ½ hr before inj). Local pain,
hypertension w/ tachycardia; Gl disturbances, burning sensation
of lips, mouth, throat, eyes; salivation, lacrimation; conjunctivitis;
rhinorrhea; muscle spasm; abdominal pain, headache, tingling
of extremities, feeling of chest or throat constriction,
sweating. In childn, fever after 2nd or 3rd inj, until treatment
ends.
Fe supplements must not be taken during therapy.
Desferrioxamine methanesulfonate.
Chronic Fe overload; eg transfusional haemosiderosis,
esp in thalassaemia major; idiopathic haemochromatosis in
patient in whom concomitant disorders preclude phlebotomy;
porphyria cutanea tarda. Acute Fe poisoning. Chronic Al
overload in renal patient on maintenance dialysis w/, for
eg Al-related bone disease &/or encephalopathy. Test
for Fe or Al overload.
Discontinue therapy if infected w/ Yersinia enterocolitica
& Yersinia pseudotuberculosis. Perform ophth & audiological
tests before & during treatment )if disturbances occur,
discontinue therapy). Severe renal failure or anuria (in
non-dialysed patient): Rate of IV infusion not > 15 mg/kg/hr.
Pregnancy.
rarely, allergic skin reactions, anaphylactic reactions,
local irritation at administration site, disturbances of
vision & hearing, opacities of the lens, Gl disturbances,
leg cramps, renal or hepatic impairment, thrombocytopenia,
CV & neurological disturbances.
Leucovorin Ca.
Leucovorin rescue after high-dose methotrexate therapy,
impaired methotrexate elimination or inadvertent over dosage.
Pernicious anaemia & other megaloblastic anaemia
where vit B12 is deficient.
Parenteral administration is preferable if there is
possibility of vomiting. Must be administered promptly as
possible in accidental over-dosage of folic acid antagonists
like MTX. Pregnancy & lactation. Elderly.
Allergic sensitization including anaphylactoid reactions
& urticaria.
Naltrexone HCI.
Adjunct to the maintenance of the opioid-free state in
detoxified formerly opioid-dependent individuals.
Insomnia, anxiety, nervousness, abdominal pain/cramps,
nausea/vomiting, low energy, joint/muscle pain, headache,
loss of appetite, diarrhea, constipation, increased thirst,
increased energy, feeling down, irritability, dizziness,
skin rash, delayed ejaculation, decreased potency &
chills.
Patients taking Trexan may not benefit from opioid containing
medicines.
Mesna.
Prevention of urotoxic effects of oxazaphosphorines.
Protective effect applies only to the urinary tract.
Gl effects, headache, malaise, skin rash. Allergic symptoms
(rare). Vein irritation.
